Pharma Nobis LLC Initiates Class II Recall for Magnesium Citrate Due to Acetobacter nitrogenifigens Contamination
Pharma Nobis LLC has initiated a Class II recall for 24,684 bottles of Magnesium Citrate Saline Laxative due to Acetobacter nitrogenifigens bacterial contamination. This voluntary, firm-initiated action, distributed nationwide by AmerisourceBergen, underscores critical quality control vulnerabilities in non-sterile pharmaceutical manufacturing. Procurement and regulatory teams must reassess supplier qualification and microbial testing protocols for oral solutions.
FDA Mandates Class II Recall for Contaminated Magnesium Citrate Oral Solution
Pharma Nobis LLC has initiated a voluntary, firm-initiated Class II recall, designated D-0227-2024, for its Good Neighbor Pharmacy, DYE FREE, SUGAR FREE Magnesium Citrate Saline Laxative, Oral Solution, Cherry Flavor 10 fl. oz. This critical regulatory action, initiated on December 21, 2023, and classified by the FDA on January 12, 2024, stems from the confirmed presence of *Acetobacter nitrogenifigens* bacteria within the non-sterile product. The recall specifically impacts 24,684 bottles across two distinct lots: A80673 and A80742, both bearing an expiration date of October 31, 2025. The affected product, identified by NDC 46122-741-38, was manufactured in Texarkana, TX, and distributed nationwide. For procurement directors, this event necessitates an immediate review of all existing contracts and quality agreements with Pharma Nobis LLC, particularly for non-sterile oral solutions. The presence of microbial contamination, even in a Class II recall, signals a significant lapse in Good Manufacturing Practices (GMP) and poses potential health risks, especially for immunocompromised individuals or those with underlying conditions. Regulatory affairs heads must assess the implications for product registration and market access, as such quality deviations can trigger heightened scrutiny from global health authorities.
Supply Chain Exposure: AmerisourceBergen and Nationwide Distribution Impact
The recall of Pharma Nobis LLC's Magnesium Citrate directly impacts AmerisourceBergen, which is listed as the distributor for the affected product (1 West First Ave, Conshohocken, PA 19428). With a distribution pattern described as 'Nationwide,' this event creates significant logistical and commercial challenges across the United States. Supply chain VPs must immediately assess the extent of their inventory holding and distribution channels for the recalled lots A80673 and A80742. The 24,684 bottles represent a substantial volume requiring efficient retrieval and quarantine to prevent further patient exposure and mitigate potential liability. For business development executives, this incident highlights the critical importance of robust due diligence on manufacturing partners, even for over-the-counter (OTC) products. A distributor's reputation can be significantly affected by quality issues originating from their suppliers. This recall mandates a comprehensive audit of quality assurance protocols for all distributed non-sterile products, ensuring that manufacturers adhere to stringent microbial control standards. The cost of managing such a recall, including reverse logistics, customer communication, and potential legal ramifications, can be substantial, underscoring the need for proactive risk management in supplier selection.
Broader Industry Context: Systemic Quality Control Risks in Non-Sterile Products
This Class II recall of Magnesium Citrate by Pharma Nobis LLC due to *Acetobacter nitrogenifigens* contamination is not an isolated incident but rather indicative of broader systemic challenges in pharmaceutical quality control, particularly for non-sterile products. Recent parallel events in the industry underscore this vulnerability. For instance, Pfizer has faced Class I recalls for Bleomycin Injection and Sodium Bicarbonate Injection due to glass particulate matter, highlighting critical manufacturing process control issues. Similarly, Sandoz’s Enoxaparin Sodium recall and Teva Pharmaceuticals’ Warfarin Sodium recall, along with Allergan’s ARMOUR THYROID, have all been linked to critical CGMP deviations such as temperature excursion risks during storage or distribution. While the specific nature of the contamination differs, these events collectively signal a persistent industry-wide struggle with maintaining consistent quality and preventing deviations. Regulatory affairs heads must recognize that microbial contamination, like particulate matter or temperature excursions, represents a fundamental failure in quality systems. This necessitates a proactive approach to supplier audits, focusing on environmental monitoring programs, water system validation, and aseptic or controlled manufacturing processes for non-sterile liquids. The recurring nature of these issues, even among major pharmaceutical players, emphasizes that no company is immune to such risks, demanding continuous vigilance and investment in robust quality management systems.
Regulatory Outlook and Business Impact for Pharma Nobis LLC
The FDA's classification of this recall as Class II indicates that the use of or exposure to the contaminated Magnesium Citrate product may cause temporary or medically reversible adverse health consequences, or that the probability of serious adverse health consequences is remote. However, the 'Ongoing' status of the recall, initiated on December 21, 2023, suggests that the FDA continues to monitor Pharma Nobis LLC's actions to ensure complete removal of the affected 24,684 bottles from the market. For business development executives, this recall can significantly impact Pharma Nobis LLC's market reputation and future commercial opportunities, particularly with major distributors like AmerisourceBergen. Future contracts may be subject to more stringent quality clauses and increased audit frequency. Regulatory affairs heads should anticipate heightened scrutiny from the FDA, potentially leading to inspections of the Texarkana, TX facility to verify corrective and preventive actions (CAPAs) addressing the root cause of the *Acetobacter nitrogenifigens* contamination. Failure to implement effective CAPAs could escalate regulatory actions, including potential Warning Letters or even import alerts if products were destined for international markets. Procurement directors should consider this event a critical data point in their supplier risk assessments, evaluating the long-term viability and reliability of Pharma Nobis LLC as a supplier for essential OTC products.